{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:49:04Z","timestamp":1769514544945,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11596-023-2719-4","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T05:01:37Z","timestamp":1690434097000},"page":"794-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A"],"prefix":"10.1007","volume":"43","author":[{"given":"Shao-hai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-yong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na-er","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suo","family":"Suo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"5","key":"2719_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer, 2005,5(5):355\u2013366","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2719_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol, 2007,18(5):945\u2013949","journal-title":"Ann Oncol"},{"issue":"3","key":"2719_CR3","first-page":"343","volume":"18","author":"Y Sonoda","year":"2004","unstructured":"Sonoda Y. Management of early ovarian cancer. Oncology (Williston Park), 2004,18(3):343\u2013356","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"2719_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett, 2008,272(2):177\u2013185","journal-title":"Cancer Lett"},{"issue":"12","key":"2719_CR5","first-page":"4837","volume":"61","author":"A Frankel","year":"2001","unstructured":"Frankel A, Rosen K, Filmus J, et al. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl\u2013X(L). Cancer Res, 2001,61(12):4837\u20134841","journal-title":"Cancer Res"},{"issue":"5","key":"2719_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1172\/JCI40802","volume":"120","author":"AK Sood","year":"2010","unstructured":"Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest, 2010,120(5):1515\u20131523","journal-title":"J Clin Invest"},{"issue":"2","key":"2719_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.gde.2004.02.001","volume":"14","author":"R Cao","year":"2004","unstructured":"Cao R, Zhang Y. The functions of E(Z)\/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev, 2004,14(2):155\u2013164","journal-title":"Curr Opin Genet Dev"},{"issue":"6990","key":"2719_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004,429(6990):457\u2013463","journal-title":"Nature"},{"issue":"3","key":"2719_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol, 2018,20(3):285\u2013295","journal-title":"Nat Cell Biol"},{"issue":"7646","key":"2719_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nature21671","volume":"543","author":"Y Xiang","year":"2017","unstructured":"Xiang Y, Laurent B, Hsu CH, et al. RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response. Nature, 2017,543(7646):573\u2013576","journal-title":"Nature"},{"issue":"2","key":"2719_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","volume":"22","author":"H Weng","year":"2018","unstructured":"Weng H, Huang H, Wu H, et al. METTL14 Inhibits Hematopoietic Stem\/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell, 2018,22(2):191\u2013205.e9","journal-title":"Cell Stem Cell"},{"issue":"1\u20132","key":"2719_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cell.2017.11.031","volume":"172","author":"R Su","year":"2018","unstructured":"Su R, Dong L, Li C, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO\/m(6)A\/MYC\/CEBPA Signaling. Cell, 2018,172(1\u20132):90\u2013105.e23","journal-title":"Cell"},{"issue":"6907","key":"2719_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002,419(6907):624\u2013629","journal-title":"Nature"},{"issue":"2","key":"2719_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol, 2006,24(2):268\u2013273","journal-title":"J Clin Oncol"},{"issue":"24Pt1","key":"2719_CR15","doi-asserted-by":"publisher","first-page":"8570","DOI":"10.1158\/1078-0432.CCR-05-1047","volume":"11","author":"JD Raman","year":"2005","unstructured":"Raman JD, Mongan NP, Tickoo SK, et al. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res, 2005,11(24 Pt 1):8570\u20138576","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2719_CR16","first-page":"4263","volume":"24","author":"WW Chen","year":"2020","unstructured":"Chen WW, Qi JW, Hang Y, et al. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA. Eur Rev Med Pharmacol Sci, 2020,24(8):4263\u20134270","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"2719_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4161\/cbt.10.8.12913","volume":"10","author":"S Hu","year":"2010","unstructured":"Hu S, Yu L, Li Z, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther, 2010,10(8):788\u2013795","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2719_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1349-7006.2010.01836.x","volume":"102","author":"J Guo","year":"2011","unstructured":"Guo J, Cai J, Yu L, et al. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci, 2011,102(3):530\u2013539","journal-title":"Cancer Sci"},{"issue":"3","key":"2719_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","volume":"7","author":"M Sauvageau","year":"2010","unstructured":"Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell, 2010,7(3):299\u2013313","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2719_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2353\/ajpath.2009.090042","volume":"175","author":"X Li","year":"2009","unstructured":"Li X, Gonzalez ME, Toy K, et al. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol, 2009,175(3):1246\u20131254","journal-title":"Am J Pathol"},{"issue":"1","key":"2719_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/fon.10.157","volume":"7","author":"A Piunti","year":"2011","unstructured":"Piunti A, Pasini D. Epigenetic factors in cancer development: polycomb group proteins. Future Oncol, 2011,7(1):57\u201375","journal-title":"Future Oncol"},{"issue":"24","key":"2719_CR22","doi-asserted-by":"publisher","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","volume":"69","author":"ML Suva","year":"2009","unstructured":"Suva ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res, 2009,69(24):9211\u20139218","journal-title":"Cancer Res"},{"issue":"2","key":"2719_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1158\/1535-7163.MCT-10-0788","volume":"10","author":"S Rizzo","year":"2011","unstructured":"Rizzo S, Hersey JM, Mellor P, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther, 2011,10(2):325\u2013335","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2719_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/onc.2008.433","volume":"28","author":"ME Gonzalez","year":"2009","unstructured":"Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene, 2009,28(6):843\u2013853","journal-title":"Oncogene"},{"key":"2719_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1476-4598-10-40","volume":"10","author":"F Crea","year":"2011","unstructured":"Crea F, Hurt EM, Mathews LA, et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer, 2011,10:40","journal-title":"Mol Cancer"},{"issue":"1","key":"2719_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-018-0590-8","volume":"11","author":"Y Pan","year":"2018","unstructured":"Pan Y, Ma P, Liu Y, et al. Multiple functions of m(6) A RNA methylation in cancer. J Hematol Oncol, 2018,11(1):48","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2719_CR27","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.celrep.2017.02.059","volume":"18","author":"Q Cui","year":"2017","unstructured":"Cui Q, Shi H, Ye P, et al. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep, 2017,18(11):2622\u20132634","journal-title":"Cell Rep"},{"issue":"1","key":"2719_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ccell.2016.11.017","volume":"31","author":"Z Li","year":"2017","unstructured":"Li Z, Weng H, Su R, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell, 2017,31(1):127\u2013141","journal-title":"Cancer Cell"},{"issue":"2","key":"2719_CR29","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1021\/acs.analchem.5b03962","volume":"88","author":"W Huang","year":"2016","unstructured":"Huang W, Qi CB, Lv SW, et al. Determination of DNA and RNA methylation in circulating tumor cells by mass spectrometry. Anal Chem, 2016,88(2):1378\u20131384","journal-title":"Anal Chem"},{"issue":"6","key":"2719_CR30","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology, 2018,67(6):2254\u20132270","journal-title":"Hepatology"},{"issue":"8","key":"2719_CR31","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1158\/0008-5472.CAN-09-3557","volume":"70","author":"X He","year":"2010","unstructured":"He X, Ota T, Liu P, et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res, 2010,70(8):3109\u20133118","journal-title":"Cancer Res"},{"issue":"20","key":"2719_CR32","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","volume":"22","author":"AP Bracken","year":"2003","unstructured":"Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J, 2003,22(20):5323\u20135335","journal-title":"EMBO J"},{"issue":"1","key":"2719_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2007.12.005","volume":"13","author":"J Lee","year":"2008","unstructured":"Lee J, Son MJ, Woolard K, et al. Epigenetic mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell, 2008,13(1):69\u201380","journal-title":"Cancer Cell"},{"issue":"5","key":"2719_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/mc.22782","volume":"57","author":"S Zhou","year":"2018","unstructured":"Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. Mol Carcinog, 2018,57(5):590\u2013597","journal-title":"Mol Carcinog"},{"issue":"1","key":"2719_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-017-0410-6","volume":"10","author":"CT Kwok","year":"2017","unstructured":"Kwok CT, Marshall AD, Rasko JE, et al. Genetic alterations of m(6)A regulators predict poorer survival in acute myeloid leukemia. J Hematol Oncol, 2017,10(1):39","journal-title":"J Hematol Oncol"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-023-2719-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:14:35Z","timestamp":1692681275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-023-2719-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2719"],"URL":"https:\/\/doi.org\/10.1007\/s11596-023-2719-4","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"2 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}